iShares Nasdaq Biotechnology ETF Stock Forecast, Price & News

+0.09 (+0.06 %)
(As of 04/22/2021 12:00 AM ET)
Today's Range
Now: $154.66
50-Day Range
MA: $151.63
52-Week Range
Now: $154.66
Volume5.06 million shs
Average Volume3.37 million shs
Market Capitalization$10.10 billion
P/E RatioN/A
Dividend Yield0.25%
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund’s investment advisor is BlackRock Fund Advisors, which is indirectly owned by BlackRock, Inc.
iShares Nasdaq Biotechnology ETF logo

Basic Details

Issuer BlackRock
Fund NameiShares Nasdaq Biotechnology ETF
Tax ClassificationRegulated Investment Company
Inception Date2/5/2001
Fund ManagerDiane Hsiung, Jennifer Hsui, Greg Savage, Alan Mason

Fund Focus

Asset ClassEquity
BenchmarkNASDAQ Biotechnology Index
FocusHealth Care
Development LevelDeveloped Markets
RegionNorth America

Fund Statistics

Assets Under Management$7.70 billion
Average Daily Volume$2.62 million

ETF Expenses

Management Fee0.47%
Other Expenses0.00%
Total Expenses0.47%
Fee Waiver0.00%
Net Expenses0.47%

Administrator, Advisor and Custodian

AdministratorState Street Bank and Trust Company
AdvisorBlackRock Fund Advisors
CustodianState Street Bank and Trust Company
DistributorBlackRock Investments, LLC
Transfer AgentState Street Bank and Trust Company
Lead Market MakerVirtu Financial

Geographic Exposure of IBB

Currency Exposure of IBB

Sector Exposure of IBB

Industry Exposure of IBB

+0.09 (+0.06 %)
(As of 04/22/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IBB News and Ratings via Email

Sign-up to receive the latest news and ratings for IBB and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) Frequently Asked Questions

What stocks does MarketBeat like better than iShares Nasdaq Biotechnology ETF?

Wall Street analysts have given iShares Nasdaq Biotechnology ETF a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but iShares Nasdaq Biotechnology ETF wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How has iShares Nasdaq Biotechnology ETF's stock price been impacted by Coronavirus (COVID-19)?

iShares Nasdaq Biotechnology ETF's stock was trading at $106.97 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, IBB stock has increased by 44.6% and is now trading at $154.66.
View which stocks have been most impacted by COVID-19

Is iShares Nasdaq Biotechnology ETF a good dividend stock?

iShares Nasdaq Biotechnology ETF pays an annual dividend of $0.39 per share and currently has a dividend yield of 0.25%.
View iShares Nasdaq Biotechnology ETF's dividend history.

When did iShares Nasdaq Biotechnology ETF's stock split? How did iShares Nasdaq Biotechnology ETF's stock split work?

iShares Nasdaq Biotechnology ETF shares split before market open on Friday, December 1st 2017. The 3-1 split was announced on Tuesday, November 7th 2017. The newly issued shares were issued to shareholders after the market closes on Thursday, November 30th 2017. An investor that had 100 shares of iShares Nasdaq Biotechnology ETF stock prior to the split would have 300 shares after the split.

Who are iShares Nasdaq Biotechnology ETF's key executives?

iShares Nasdaq Biotechnology ETF's management team includes the following people:
  • George G. C. Parker Ph.D., Independent Chairman of the Board of Trustees
  • Michael Arthur Latham, President, Trustee
  • Jack Gee, Chief Financial Officer, Treasurer
  • Geoffrey D. Flynn, Chief Operating Officer, Executive Vice President
  • , Bio & Compensation - 
  • Amy Schioldager, Executive Vice President
  • Ira P. Shapiro, Vice President, Chief Legal Officer
  • Matt Tucker, Vice President
  • , Bio & Compensation - 
  • Eilleen M. Clavere, Secretary
  • Cecilia H. Herbert, Independent Trustee
  • Charles A. Hurty, Independent Trustee

Who are some of iShares Nasdaq Biotechnology ETF's key competitors?

What other stocks do shareholders of iShares Nasdaq Biotechnology ETF own?

Based on aggregate information from My MarketBeat watchlists, some companies that other iShares Nasdaq Biotechnology ETF investors own include NVIDIA (NVDA), The Walt Disney (DIS), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Cisco Systems (CSCO), Micron Technology (MU), Bank of America (BAC), Johnson & Johnson (JNJ) and PayPal (PYPL).

What is iShares Nasdaq Biotechnology ETF's stock symbol?

iShares Nasdaq Biotechnology ETF trades on the NASDAQ under the ticker symbol "IBB."

Who are iShares Nasdaq Biotechnology ETF's major shareholders?

iShares Nasdaq Biotechnology ETF's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Crestwood Advisors Group LLC (0.21%), CHURCHILL MANAGEMENT Corp (0.11%), McGuire Investment Group LLC (0.10%), Valicenti Advisory Services Inc. (0.10%), Toth Financial Advisory Corp (0.09%) and Appleton Partners Inc. MA (0.08%).

Which major investors are selling iShares Nasdaq Biotechnology ETF stock?

IBB stock was sold by a variety of institutional investors in the last quarter, including CHURCHILL MANAGEMENT Corp, Crestwood Advisors Group LLC, M&R Capital Management Inc., Chesley Taft & Associates LLC, NEXT Financial Group Inc, Tatro Capital LLC, Aurora Investment Managers LLC., and F&V Capital Management LLC.

Which major investors are buying iShares Nasdaq Biotechnology ETF stock?

IBB stock was purchased by a variety of institutional investors in the last quarter, including McGuire Investment Group LLC, HBW Advisory Services LLC, Rye Brook Capital LLC, Capital Wealth Planning LLC, Fulcrum Equity Management, Harbour Capital Advisors LLC, International Assets Investment Management LLC, and SPC Financial Inc..

How do I buy shares of iShares Nasdaq Biotechnology ETF?

Shares of IBB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is iShares Nasdaq Biotechnology ETF's stock price today?

One share of IBB stock can currently be purchased for approximately $154.66.

How much money does iShares Nasdaq Biotechnology ETF make?

iShares Nasdaq Biotechnology ETF has a market capitalization of $10.10 billion.

This page was last updated on 4/23/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.